Skip to main content

Advertisement

Springer Nature Link
Log in

The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Mutations in the KRAS gene have been shown to play a key role in the pathogenesis of a variety of human tumours. However the mutational spectrum of KRAS gene differs by organ site. In this study, we have analysed the mutational spectrum of KRAS exon 1 in bladder tumours, colorectal cancer (CRC) and chronic myeloid leukemia (CML). A total of 366 patients were included in the present study (234 bladder tumours, 48 CRC and 84 CML). The KRAS mutations are absent in BCR/ABL1 positive CML. This result suggests that BCR/ABL1 fusion gene and KRAS mutations were mutually exclusive. The frequency of KRAS mutations in bladder cancer was estimated at 4.27 %. All of mutations were found in codon 12 and 90 % of them were detected in advanced bladder tumours. However the correlation between KRAS mutations and tumour stage and grade does not report a statistical significant association. The KRAS mutations occur in 35.41 % of patients with CRC. The most frequent mutations were G12C, G12D and G13D. These mutations were significantly correlated with histological differentiation of CRC (p = 0.024). Although the high frequency of KRAS in CRC in comparison to bladder cancer, these two cancers appear to have the same mutational spectrum (p > 0.05).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Johnson L, Greenbaum D, Cichowski K et al (1997) K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 11:2468–2481

    Article  PubMed  CAS  Google Scholar 

  2. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3(1):11–22

    Article  PubMed  CAS  Google Scholar 

  3. Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3:459–465

    Article  PubMed  CAS  Google Scholar 

  4. Mitin N, Rossman K, Der C (2005) Signaling interplay in Ras super family function. Curr Biol 15:563–574

    Article  Google Scholar 

  5. Prior IA, Lewis PD, Mattos C (2012) A comprehensive survey of Ras mutations in cancer. Cancer Res 72(10):2457–2467

    Article  PubMed  CAS  Google Scholar 

  6. Calistri D, Rengucci C, Seymour I et al (2005) Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol 204:484–488

    Article  PubMed  CAS  Google Scholar 

  7. Saridaki Z, Georgoulias V, Souglakos J (2010) Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol 16:1177–1187

    Article  PubMed  CAS  Google Scholar 

  8. Zeegers MP, Tan FE, Dorant E, Van Den Brandt PA (2000) The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89:630–639

    Article  PubMed  CAS  Google Scholar 

  9. Cordon-Cardo C (2008) Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl 218:154–165

    Article  PubMed  Google Scholar 

  10. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O et al (2010) Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 28:401–408

    Article  PubMed  CAS  Google Scholar 

  11. Czerniak B (2010) Molecular pathology and biomarkers of bladder cancer. Cancer Biomark 9:159–176

    PubMed  Google Scholar 

  12. Zhang ZT, Pak J, Huang HY et al (2001) Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 20:1973–1980

    Article  PubMed  CAS  Google Scholar 

  13. Jebar AH, Hurst CD, Tomlinson DC et al (2005) FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24:5218–5225

    Article  PubMed  CAS  Google Scholar 

  14. Kompier LC, Lurkin I, Van der Aa MN et al (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5:13821

    Article  Google Scholar 

  15. He LZ, Stephenson J, He GY, Mufti GJ (1996) RAS gene mutations in Chinese leukaemia patients and members of a family with high incidence of leukaemia. Leuk Res 11–12:901–903

    Article  Google Scholar 

  16. Conti CJ (1992) Mutations of genes of the ras family in humanand experimental tumors. In: Klein-Szanto AJP, Anderson MW, Barrett JC, Slaga TJ (eds) Comparative Molecular Carcinogenesis. Wiley-Liss, Inc., NewYork, pp 357–378

    Google Scholar 

  17. Al-Mulla F, MacKenzie EM (2001) Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol 195:549–556

    Article  PubMed  CAS  Google Scholar 

  18. Collins SJ, Howard M, Andrews DF, Agura E, Radich J (1989) Rare occurrence of N-RAS point mutations in Philadelphia chromosome positive chronic myeloid leukaemia. Blood 73:1028

    PubMed  CAS  Google Scholar 

  19. Jankowska AM, Makishima H, Tiu RV et al (2011) Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118(14):3932–3941

    Article  PubMed  CAS  Google Scholar 

  20. Agarwal A, Eide CA, Harlow A, Corbin AS et al (2008) An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. Leukemia 22(12):2269–2272

    Article  PubMed  CAS  Google Scholar 

  21. Karimianpour N, Mousavi-Shafaei P, Ziaee AA et al (2008) Mutations of RAS gene family in specimens of bladder cancer. Urol J 5(4):237–242

    PubMed  Google Scholar 

  22. Nanda MS, Sameer AS, Syeed N et al (2010) Genetic aberrations of the K-ras proto-oncogene in bladder cancer in Kashmiri population. Urol J 7(3):168–173

    PubMed  Google Scholar 

  23. Uchida T, Wada C, Ishida H et al (1995) Infrequent involvement of mutations on neurofibromatosis type 1, H-ras, K-ras and N-ras in urothelial tumors. Urol Int 55:63–67

    Article  PubMed  CAS  Google Scholar 

  24. Olderoy G, Daehlin L, Ogreid D (1998) Low-frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder. Anticancer Res 18:2675–2678

    PubMed  CAS  Google Scholar 

  25. Miller MS, Miller LD (2011) RAS mutations and oncogenesis: not all RAS mutations are created equally. Front Genet 2:100

    PubMed  Google Scholar 

  26. Seo KY, Jelinsky SA, Loechler EL (2000) Factors that influence the mutagenic patterns of DNA adducts from chemical carcinogens. Mutat Res 463:215–246

    Article  PubMed  CAS  Google Scholar 

  27. Barbacid M (1990) Ras oncogenes: their role in neoplasia. Eur J Clin Invest 20:225–235

    Article  PubMed  CAS  Google Scholar 

  28. Capella G, Cronauer-Mitra S, Pienado MA, Perucho M (1991) Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect 93:125–131

    Article  PubMed  CAS  Google Scholar 

  29. De Roock W, Jonker DJ, Di Nicolantonio F et al (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812–1820

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank François Radvanyi and Aurélie Herault from the Institut Curie (UMR144 CNRS, Paris, France) andYves Allory, Karène Leroy from the Henri Mondor hospital (Créteil, France) for their help in this work.

Conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Laboratory of Molecular and Cellular Haematology, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis, Tunisia

    Slah Ouerhani, Ismail Soltani, Salem Abbes & Samia Menif

  2. Laboratory of Genetics, Immunology and Human Pathology, Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis, Tunisia

    Karim Bougatef & Amel Ben Ammar Elgaaied

Authors
  1. Slah Ouerhani
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Karim Bougatef
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Ismail Soltani
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Amel Ben Ammar Elgaaied
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Salem Abbes
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Samia Menif
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Slah Ouerhani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ouerhani, S., Bougatef, K., Soltani, I. et al. The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer. Mol Biol Rep 40, 4109–4114 (2013). https://doi.org/10.1007/s11033-013-2512-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-013-2512-8

Keywords